Financial Information
This section houses up-to-date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Sera Prognostics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQSERA
| Beta | 0.97 |
|---|---|
| Shares Outstanding | 39.2M |
| Average Volume (10 days) | 38.6K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 4 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Austin Aerts Chief Financial Officer | (2,037) Sell Jun 11, 2026 |
|---|---|
Inglis Tiffany Eul Davis Chief Medical Officer | (362) Sell Jun 11, 2026 |
Anderson Dyaarl Lee Jr. Chief Commercial Officer | (4,739) Sell Jun 11, 2026 |
Benjamin Jackson General Counsel | (2,179) Sell Jun 11, 2026 |
Zhenya Lindgardt Director | (6,990) Sell Jun 11, 2026 |
Email Alerts
Sign up for our investor relations email list here.